Physicians' Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Physicians' Education Resource®, LLC, designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physicians' Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669 for 2.0 Contact Hours.
PER Pulse™ Recaps
The 1st Annual School of Gastrointestinal Oncology™ (SOGO™), which was held April 23, 2016, presented the latest data on the multidisciplinary management of patients with gastrointestinal cancers, including colorectal cancer (CRC), gastric cancer, pancreatic cancer, hepatocellular carcinoma, and others.
This activity is supported by educational grants from Celgene, Lilly, Sirtex, and Taiho Oncology, Inc.
For further information concerning Lilly grant funding, visit www.lillygrantoffice.com.
Community Practice Connections™: 1st Annual School of Gastrointestinal Oncology™ consists of a series of brief interviews with noted thought leaders exploring questions from the community physician perspective. The video interviews address decision points in the clinical vignettes, as well as questions commonly faced in the community oncology practice setting.
Instructions For This Activity & Receiving Credit
This educational activity is directed toward oncologists, as well as surgeons, pathologists, nurses, and fellows involved in the treatment and management of patients with gastrointestinal (GI) cancers. Physician assistants, pharmacists, researchers, and other healthcare professionals interested in the treatment of GI malignancies may also participate.
Ghassan K. Abou-Alfa, MD
Gastrointestinal Oncology Service
Memorial Sloan Kettering Cancer Center
New York, NY
Michael A Choti, MD, MBA, FACS
Professor and Chair
Department of Surgery
UT Southwestern Medical Center
John Marshall, MD
Chief, Division of Hematology/Oncology
Georgetown University Hospital
Director, Ruesch Center for the Cure of GI Cancers
The following individuals have no relevant financial relationships with commercial interests:
The staff of Physicians’ Education Resource®, LLC
Michael A. Choti, MD, MBA, FACS
The following individuals have relevant financial relationships with commercial interests to disclose:Ghassan K. Abou-Alfa, MD: Grant/Research Support -- Abbott Laboratories, Amgen, Bayer, Celgene, Eli Lilly and Company/ImClone, Exelixis, Genentech, Immunomedics, Incyte, Momenta Pharmaceuticals, Myriad Genetics, Novartis, OncoMed Pharmaceuticals, Polaris Pharmaceuticals, Roche, Vicus Therapeutics; Consultant -- Aduro Biotech, Array BioPharma, Astellas Pharma US, BioAlliance, Boston Scientifc, Boston Therapeutics, Bristol-Myers Squibb, CASI Pharmaceuticals, Celgene, Cipla, Eli Lilly and Company, Gilead Sciences, IntegraGen, MedImmune, Merrimack, Momenta, Novartis, Onxeo, Pharmacyclics, sanofi-aventis, Silenseed, SillaJen, Vicus Therapeutics; John Marshall, MD: Grant/Research Support -- Genentech, Amgen, Bayer, Celgene; Consultant -- Genentech, Amgen, Celgene, Bayer, Indivumed, Caris; Speakers Bureau -- Genentech, Amgen, Bayer, Celgene
It is the policy of Physicians' Education Resource®, LLC, (PER®) to ensure fair balance, independence, objectivity, and scientific rigor in all of our CME/CE activities. In accordance with ACCME guidelines, PER® requires everyone who is in a position to control the content of an educational activity, including spouses/partners, to disclose all relevant financial relationships with any commercial interest to participants as a part of the activity planning process. PER® has implemented mechanisms to identify and resolve all conflicts of interest prior to release of this activity.
This CME/CE activity may or may not discuss investigational, unapproved, or off-label uses of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME/CE activity is for continuing medical education purposes only, and is not meant to substitute for the independent medical judgment of a physician or nurse relative to diagnostic, treatment, or management options for a specific patient's medical condition.
The opinions expressed in the content are solely those of the individual faculty members, and do not reflect those of Physicians' Education Resource®, LLC, or any of the companies that provided commercial support for this activity.
ONS: PER Forum™: Nursing Opportunities to Improve Outcomes With the Advent of PARP Inhibitors in the Care of Women’s Cancers
May 17, 2018
ONS: Working Group for Changing Standards in EGFR-Mutated Lung Cancers: Real-World Applications of the Evidence for Nurses
May 17, 2018
Medical Crossfire®: Clinical Updates on PARP Inhibition and its Evolving Use in the Treatment of Cancers
May 30, 2018
May 31, 2018
May 31, 2018